First-Person Psychopharmacology: This is Normal Care

Abstract

The author considers how the medical standard of care in depression treatment has shaped the course of her life. She recounts how she developed depression in childhood and, as a member of the demographic targeted by pharmaceutical marketing for antidepressants in the 1990s, how she came to be treated with the new selective serotonin reuptake inhibitor drugs, her experiences with her prescribers, and her recovery from disabling protracted antidepressant withdrawal syndrome. As a citizen scientist, she incorporates learnings from the history and practice of psychopharmacology and her own research into a personal narrative of what has become normal care for depression.

Keywords

depression psychiatry antidepressant selective serotonin reuptake inhibitor SSRI iatrogenic withdrawal withdrawal syndrome discontinuation syndrome post-acute withdrawal prolonged withdrawal protracted withdrawal PAWS PWS

Get full access to this article

View all access options for this article.

References

Ables

A. Z.

Baughman

O. L.

(2003). Antidepressants: Update on new agents and indications. American Family Physician, 67(3), 547–554. https://www.aafp.org/pubs/afp/issues/2003/0201/p547.html

Aikins

R. D.

(2015). From recreational to functional drug use: The evolution of drugs in American higher education, 1960–2014. History of Education, 44(1), 25–43. https://doi.org/10.1080/0046760X.2014.979251

Andrade

(2004). Antidepressant-withdrawal mania: A critical review and synthesis of the literature. The Journal of Clinical Psychiatry, 65(7), 987–993. https://doi.org/10.4088/JCP.v65n0716

Ashton

C. H.

(1995). Protracted withdrawal from benzodiazepines: The post-withdrawal syndrome. Psychiatric Annals, 25(3), 174–179. https://doi.org/10.3928/0048-5713-19950301-11

Aviv

(2019, April 1). The challenge of going off psychiatric drugs. The New Yorker, April 8, 2019. https://www.newyorker.com/magazine/2019/04/08/the-challenge-of-going-off-psychiatric-drugs

Baldwin

C. M.

Bell

I. R.

Fernandez

Schwartz

G. E. R.

(2000). Multiple chemical sensitivity. In Women and Health (pp. 1129–1139). Elsevier. https://doi.org/10.1016/B978-012288145-9/50103-0

Baston

(2005). Paxil withdrawal guide. Saga Books.

Belaise

Gatti

Chouinard

V.-A.

Chouinard

(2012). Patient online report of selective serotonin reuptake inhibitor-Induced persistent postwithdrawal anxiety and mood disorders. Psychotherapy and Psychosomatics, 81(6), 386–388. https://doi.org/10.1159/000341178

Berntsen

(2021). Involuntary autobiographical memories and their relation to other forms of spontaneous thoughts. Philosophical transactions of the royal society of London, Series B, Biological Sciences, 376(1817), 20190693. https://doi.org/10.1098/rstb.2019.0693

10.

Bhasale

A. L.

Sarpatwari

Lipworth

Møllebæk

McEwin

E. J.

Gautam

Santiago Ortiz

Mintzes

B. J.

(2022). Regulatory authority and clinical acceptability: Physicians’ responses to regulatory drug safety warnings. British Journal of Clinical Pharmacology, 88(2), 713–722. https://doi.org/10.1111/bcp.15007

11.

Black

D. W.

(2021). Managing “difficult” patient encounters. Current Psychiatry, 20(7). https://doi.org/10.12788/cp.0144

12.

Brown

(2023, July 10). In SSRI withdrawal, Brain Zaps go from overlooked symptom to center stage. Psychiatrist.Com. https://www.psychiatrist.com/news/brain-zaps-go-from-overlooked-symptom-to-center-stage-in-ssri-withdrawal/

13.

Bruggeman

O’Day

C. S.

(2022). Selective serotonin reuptake inhibitor toxicity. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK534815/

14.

Bryant

R. A.

(2015). The complex fabric of trauma and autobiographical memory. In Watson

L. A.

Berntsen

(Eds.), Clinical Perspectives on Autobiographical Memory (pp. 17–40). Cambridge University Press; Cambridge Core. https://doi.org/10.1017/CBO9781139626767.003

15.

Chouinard

V.-A.

(2015). New classification of selective serotonin reuptake inhibitor withdrawal. Psychotherapy and Psychosomatics, 84(2), 63–71. https://doi.org/10.1159/000371865

16.

Chouinard

Sultan

(1990). Treatment of supersensitivity psychosis with antiepileptic drugs: Report of a series of 43 cases. Psychopharmacology Bulletin, 26(3), 337–341.

17.

Collins

F. E.

Ffrench

C. H.

(1998). Dissociation, coping strategies, and locus of control in a non-clinical population: Clinical implications. Australian Journal of Clinical and Experimental Hypnosis, 26, 113–126. http://www.hypnosisaustralia.org.au/wp-content/uploads/journal/AJCEH_Vol26_No2_NOV98.pdf#page=36

18.

Corrow

J. C.

Corrow

S. L.

Lee

Pancaroglu

Burles

Duchaine

Iaria

Barton

J. J. S.

(2016). Getting lost: Topographic skills in acquired and developmental prosopagnosia. Cortex; a Journal Devoted to the Study of the Nervous System and Behavior, 76, 89–103. https://doi.org/10.1016/j.cortex.2016.01.003

19.

Crumlish

Kelly

B. D.

(2009). How psychiatrists think. Advances in Psychiatric Treatment, 15(1), 72–79. https://doi.org/10.1192/apt.bp.107.005298

20.

Dalrymple

K. A.

Fletcher

Corrow

Das Nair

Barton

J. J. S.

Yonas

Duchaine

(2014). “A room full of strangers every day”: The psychosocial impact of developmental prosopagnosia on children and their families. Journal of Psychosomatic Research, 77(2), 144–150. https://doi.org/10.1016/j.jpsychores.2014.06.001

21.

deBronkart

(2013). How the e-patient community helped save my life: An essay by Dave deBronkart. BMJ, 346, f1990–f1990. https://doi.org/10.1136/bmj.f1990

22.

Dharmananda

(2004, September). SSRI withdrawal procedure: Getting off antidepressants may be made easier. Institute for Traditional Medicine. http://www.itmonline.org/arts/ssri.htm

23.

Economist. (2022, October 19). How to make better use of antidepressants. The Economist. https://www.economist.com/science-and-technology/2022/10/19/how-to-make-better-use-of-antidepressants

24.

Fauber

Flore

Wynn

(2016, November 16). Lowering the bar: How PMDD went from an idea to a diagnosis. Milwaukee Journal Sentinel/MedPage Today. https://www.medpagetoday.com/special-reports/loweringthebar/61457

25.

FDA. (2001). Paxil prescribing information, attachment to FDA approval letter NDA 20-031/s-029 [FDA Approval Letter]. US Food and Drug Administration.

26.

FDA. (2002). Label for LEXAPRO (escitalopram oxalate) (Approved Drug Label NDA 21-323). US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323.pdf_Lexapro_Prntlbl.pdf

27.

FDA. (2003). Label for WELLBUTRIN XL (bupropion hydrochloride extended-release tablets) (Approved Drug Label No. NDA 21-515). US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021515_Wellbutrin_prntlbl.PDF

28.

FDA. (2024). Lamictal (lamotrigine): Drug safety communication – Studies show increased risk of heart rhythm problems in patients with heart disease. [Drug Safety Communication]. https://www.fda.gov/safety/medical-product-safety-information/lamictal-lamotrigine-drug-safety-communication-studies-show-increased-risk-heart-rhythm-problems

29.

Fixsen

A. M.

Ridge

(2017). Stories of hell and healing: Internet users’ construction of benzodiazepine distress and withdrawal. Qualitative Health Research, 27(13), 2030–2041. https://doi.org/10.1177/1049732317728053

30.

Framer

(2021). What I have learnt from helping thousands of people taper off antidepressants and other psychotropic medications. Therapeutic Advances in Psychopharmacology, 11. https://doi.org/10.1177/2045125321991274

31.

Friedan

(2010). The problem that has no name. American Journal of Public Health, 100(9), 1582–1584. https://doi.org/10.2105/AJPH.100.9.1582

32.

GlaxoSmithKline (Producer). (2004). Wellbutrin XL television commercial 2004 [Video]. https://www.youtube.com/watch?v=twhvtzd6gXA&feature=emb_logo

33.

Harris

(2009, September 1). Document details plan to promote costly drug. The New York Times. https://www.nytimes.com/2009/09/02/business/02drug.html

34.

Hayasaka

Purgato

Magni

L. R.

Ogawa

Takeshima

Cipriani

Barbui

Leucht

Furukawa

T. A.

(2015). Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials. Journal of Affective Disorders, 180, 179–184. https://doi.org/10.1016/j.jad.2015.03.021

35.

Healy

Bahrick

Bak

Barbato

Calabrò

R. S.

Chubak

B. M.

Cosci

Csoka

A. B.

D’Avanzo

Diviccaro

Giatti

Goldstein

Graf

Hellstrom

W. J. G.

Irwig

M. S.

Jannini

E. A.

Janssen

P. K. C.

Khera

Kumar

M. T.

. . . Waraich

(2022). Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin. International Journal of Risk & Safety in Medicine, 33(1), 65–76. https://doi.org/10.3233/JRS-210023

36.

Hengartner

M. P.

Schulthess

Sorensen

Framer

(2020). Protracted withdrawal syndrome after stopping antidepressants: A descriptive quantitative analysis of consumer narratives from a large internet forum. Therapeutic Advances in Psychopharmacology, 10. https://doi.org/10.1177/2045125320980573

37.

Horwitz

A. V.

(2011). Naming the problem that has no name: Creating targets for standardized drugs. Studies in History and Philosophy of Science Part C: Studies in History and Philosophy of Biological and Biomedical Sciences, 42(4), 427–433. https://doi.org/10.1016/j.shpsc.2011.05.002

38.

Keefe

P. R.

(2021). Empire of pain: The secret history of the Sackler dynasty. (First). Doubleday.

39.

Kramer

P. D.

(1997). Listening to Prozac. Penguin Books.

40.

Krempel

Monzel

(2024). Aphantasia and involuntary imagery. Consciousness and Cognition, 120, 103679. https://doi.org/10.1016/j.concog.2024.103679

41.

Lane

(2007). Shyness: How normal behavior became a sickness. Yale University Press.

42.

Lerner

Klein

(2019). Dependence, withdrawal and rebound of CNS drugs: An update and regulatory considerations for new drugs development. Brain Communications, 1(1), fcz025. https://doi.org/10.1093/braincomms/fcz025

43.

Lilly (Producer). (2005). Cymbalta “Depression Hurts” television advertisement [Video]. https://www.adforum.com/creative-work/ad/player/57679/depression-hurts/cymbalta

44.

Lockhart

Guthrie

(2011). Trends in primary care antidepressant prescribing 1995–2007: A longitudinal population database analysis. The British Journal of General Practice: The Journal of the Royal College of General Practitioners, 61(590), e565–572. https://doi.org/10.3399/bjgp11X593848

45.

Luo

Kataoka

Ostinelli

E. G.

Cipriani

Furukawa

T. A.

(2020). National prescription patterns of antidepressants in the treatment of adults with major depression in the US between 1996 and 2015: A population representative survey based analysis. Frontiers in Psychiatry, 11, 35. https://doi.org/10.3389/fpsyt.2020.00035

46.

Masdrakis

V. G.

Markianos

Baldwin

D. S.

(2023). Apathy associated with antidepressant drugs: A systematic review. Acta Neuropsychiatrica, 35(4), 189–204. https://doi.org/10.1017/neu.2023.6

47.

Michelson

Fava

Amsterdam

Apter

Londborg

Tamura

Tepner

R. G.

(2000). Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial. The British Journal of Psychiatry: The Journal of Mental Science, 176, 363–368. https://doi.org/10.1192/bjp.176.4.363

48.

Montejo-González

A. L.

Llorca

Izquierdo

J. A.

Ledesma

Bousoño

Calcedo

Carrasco

J. L.

Ciudad

Daniel

De la Gandara

Derecho

Franco

Gomez

M. J.

Macias

J. A.

Martin

Perez

Sanchez

J. M.

Sanchez

Vicens

(1997). SSRI-induced sexual dysfunction: Fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. Journal of Sex & Marital Therapy, 23(3), 176–194. https://doi.org/10.1080/00926239708403923

49.

O’Connor

A. R.

Wells

Moulin

C. J. A.

(2021). Déjà vu and other dissociative states in memory. Memory, 29(7), 835–842. https://doi.org/10.1080/09658211.2021.1911197

50.

Opbroek

Delgado

P. L.

Laukes

McGahuey

Katsanis

Moreno

F. A.

Manber

(2002). Emotional blunting associated with SSRI-induced sexual dysfunction. Do SSRIs inhibit emotional responses? The International Journal of Neuropsychopharmacology, 5(2), 147–151. https://doi.org/10.1017/S1461145702002870

51.

Paxilprogress. (2007, July 8). Paxilprogress.org home page. Paxilprogress.org. https://web.archive.org/web/20070708013011/http://www.paxilprogress.org/forums/

52.

Pfizer (Producer). (2001, May). Original Zoloft Commercial [Video]. ABC. https://www.youtube.com/watch?v=twhvtzd6gXA&feature=emb_logo

53.

Phelps

(2019, September 2). Deprescribing in psychiatry. Psychopharmacology Institute. https://psychopharmacologyinstitute.com/section/deprescribing-in-psychiatry-2330-4422

54.

Podolsky

S. H.

Herzberg

Greene

J. A.

(2019). Preying on prescribers (and their patients)—pharmaceutical marketing, iatrogenic epidemics, and the Sackler legacy. New England Journal of Medicine, 380(19), 1785–1787. https://doi.org/10.1056/NEJMp1902811

55.

Preda

MacLean

R. W.

Mazure

C. M.

Bowers

M. B.

(2001). Antidepressant-associated mania and psychosis resulting in psychiatric admissions. The Journal of Clinical Psychiatry, 62(1), 30–33. https://doi.org/10.4088/jcp.v62n0107

56.

Roche. (1963). Enjoying her family. In American Institute of the History of Pharmacy Digital Collection. AIHP Mickey Smith Drug Advertising Collection. https://aihp.omeka.net/items/show/670

57.

Sacks

(2010, August 23). Face-blind. The New Yorker. https://www.newyorker.com/magazine/2010/08/30/face-blind

58.

Shelton

R. C.

(2001). Steps following attainment of remission: Discontinuation of antidepressant therapy. Primary Care Companion to the Journal of Clinical Psychiatry, 3(4), 168–174. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC181183/

59.

Shelton

R. C.

(2006, July 22). Personal communication [Personal communication].

60.

SmithKline

Beecham

. (1997). Business plan guide: A marketing/sales guide to help you tailer your territory business plans (Sales Cycle 2, 1997: December 1, 1997–May 31, 1998). https://abcnews.go.com/images/Primetime/paxil_bpg.pdf

61.

SmithKline

Beecham

. (Producer). (2000). Paxil—2000 TV commercial [Video]. https://youtu.be/dQmNOx-gBPM?si=ju3wpDRntN37cDZB

62.

SmithKline

Beecham

. (2001). Can you imagine being allergic to people? North American Precis Syndicate. https://featurettes.mynewstouse.com/napsnet/files/20190731-213244-49514.pdf?_ga=2.128042248.520701507.1728879548-1112916984.1728879547

63.

Steiner

Steinberg

Stewart

Carter

Berger

Reid

Grover

Streiner

(1995). Fluoxetine in the treatment of premenstrual dysphoria. New England Journal of Medicine, 332(23), 1529–1534. https://doi.org/10.1056/NEJM199506083322301

64.

Stover

P. J.

(2010). Vitamin B12 and older adults. Current Opinion in Clinical Nutrition and Metabolic Care, 13(1), 24–27. https://doi.org/10.1097/MCO.0b013e328333d157

65.

Targum

S. D.

(2014). Identification and treatment of antidepressant tachyphylaxis. Innovations in Clinical Neuroscience, 11(3–4), 24–28. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4008298/

66.

Tonks

(2002). Withdrawal from paroxetine can be severe, warns FDA. BMJ, 324(7332), 260. https://doi.org/10.1136/bmj.324.7332.260

67.

UCLA Dual Diagnosis Program. (2019). Post-acute withdrawal syndrome (PAWS). UCLA Semel Institute for Neuroscience & Human Behavior. https://www.semel.ucla.edu/dual-diagnosis-program/News_and_Resources/PAWS

68.

Van Campen

. (2014). The Proust effect: The senses as doorways to lost memories. Oxford University Press. https://doi.org/10.1093/acprof:oso/9780199685875.001.0001

69.

Vaughan-Cole

(2024). Bumps in the road: 1970–1980. In History of Graduate Education in Psychiatric-Mental Health Nursing, University of Utah, 1957–2023. https://uen.pressbooks.pub/historyofgradpsycmentalhealthnursinguofutah/chapter/bumps-in-the-road-1970-1980/

70.

Vydiswaran

V. G. V.

Reddy

(2019). Identifying peer experts in online health forums. BMC Medical Informatics and Decision Making, 19(S3), 68. https://doi.org/10.1186/s12911-019-0782-3

71.

White

Read

Julo

(2021). The role of Facebook groups in the management and raising of awareness of antidepressant withdrawal: Is social media filling the void left by health services? Therapeutic Advances in Psychopharmacology, 11. https://doi.org/10.1177/2045125320981174

72.

Wisner

K. L.

Sit

D. K. Y.

Hanusa

B. H.

Moses-Kolko

E. L.

Bogen

D. L.

Hunker

D. F.

Perel

J. M.

Jones-Ivy

Bodnar

L. M.

Singer

L. T.

(2009). Major depression and antidepressant treatment: Impact on pregnancy and neonatal outcomes. American Journal of Psychiatry, 166(5), 557–566. https://doi.org/10.1176/appi.ajp.2008.08081170

73.

Witt-Doerring

Shorter

Kosten

(2018, April 18). Online communities for drug withdrawal: What can we learn? Psychiatric Times. https://www.psychiatrictimes.com/article/online-communities-drug-withdrawal-what-can-we-learn